Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 28952227
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study

  2017cited by this paper
• Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement

  2016cited by this paper
• Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma

  2016cited by this paper
• A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features

  2016cited by this paper
• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

  2015cited by this paper
• Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.

  2015cited by this paper
• Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

  2015cited by this paper
• Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non–Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI

  2015cited by this paper
• Crizotinib in ROS1-rearranged non-small-cell lung cancer.

  2014cited by this paper
• Targeting the MET gene for the treatment of non-small-cell lung cancer.

  2014influential reference
• MET Gene Copy Number Gain is an Independent Poor Prognostic Marker in Korean Stage I Lung Adenocarcinomas

  2014cited by this paper
• Correlation of MET and EGFR amplification with prognosis in non-small cell lung cancer

  2013cited by this paper
• ROS1 fusions in Chinese patients with non-small-cell lung cancer.

  2013influential reference
• Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  2013cited by this paper
• ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas

  2013cited by this paper
• New molecular targets in the treatment of NSCLC.

  2013cited by this paper
• Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm

  2013influential reference
• Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

  2012cited by this paper
• Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

  2012influential reference
• c-Met upregulates aquaporin 3 expression in human gastric carcinoma cells via the ERK signalling pathway.

  2012cited by this paper
• RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer.

  2012cited by this paper
• ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

  2012cited by this paper
• Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.

  2011cited by this paper
• HGF-independent Potentiation of EGFR Action by c-Met

  2011cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer

  2010cited by this paper
• Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.

  2009cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• Increased production and secretion of HGF α‐chain and an antagonistic HGF fragment in a human breast cancer progression model

  2009cited by this paper
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

  2008influential reference
• Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancer

  2008cited by this paper
• MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

  2008cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.

  2007cited by this paper

• Clinical characteristics of patients with ROS1 gene rearrangement in non-small cell lung cancer: a meta-analysis

  2020cites this paper
• Distribution of EGFR SNPs -191C/A and 181946G/A in patients with lung cancer depending on smoking status in the Republic of Srpska, Bosnia and Herzegovina.

  2018cites this paper